Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
Go back to Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 45.11 -0.78 (1.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.89 | 52 Week High | $4.38 | |||
| Open | $45.63 | 52 Week Low | $1.88 | |||
| Day High | $46.21 | P/E | N/A | |||
| Day Low | $44.51 | EPS | $-1.12 | |||
| Volume | 541,997 | |||||
